Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 801–900 of 1,002
Shen, L., Jin, X., Wang, X., Tou, L., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000745 · Cited by 27
“001).([53]) Further, the efficacy of palbociclib with fulvestrant was investigated in the second-line setting in the PALOMA-3 trial.”
BackgroundBrain metastases in metastatic cancer: a review of recent advances in systemic therapies
Steindl, A., & Berghoff, A. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1851200 · Cited by 26
Ribelles, N., Jerez, J. M., Rodríguez-Brazzarola, P., Jiménez, B., Díaz-Redondo, T., Mesa, H., Márquez, A., Sánchez‐Muñoz, A., Pajares, B., Carabantes, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.030 · Cited by 28
Palumbo, R., Torrisi, R., Sottotetti, F., Presti, D., Gambaro, A. R., Collovà, E., Ferzi, A., Agostinetto, E., Teragni, C. M., Saltalamacchia, G., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987651 · Cited by 26
Raimondi, L., Raimondi, F. M., Pietranera, M., Rocco, A. D., Benedetto, L. D., Miele, E., Lazzeroni, R., Cimino, G. G., & Spinelli, G. P. (2021) · Cancers · doi:10.3390/cancers13081928 · Cited by 26
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration
Raoul, J., & Hansten, P. D. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102794 · Cited by 28
Shee, K., Jiang, A., Varn, F. S., Liu, S., Traphagen, N. A., Owens, P., Ma, C. X., Hoog, J., Cheng, C., Golub, T. R., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801241r · Cited by 28
Reiter, F. P., Denk, G., Ziesch, A., Ofner, A., Wimmer, R., Hohenester, S. D., Schiergens, T. S., Spampatti, M. P., Ye, L., Itzel, T., et al. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00458-8 · Cited by 27
Xie, X., Zheng, W., Chen, T., Lin, W., Liao, Z., Liu, J., & Ding, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s234221 · Cited by 26
“Palbociclib is the first CDK4/6 inhibitor approved by the FDA as first-line treatment of advanced breast cancer.(4) Notably, palbociclib proves to be promising in managing RB-proficient germ-cell tumors, liposarcoma, melanoma in some clinical trials.”
BackgroundHui, R., BOER, R. D., Lim, E., Yeo, B. J., & Lynch, J. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13555 · Cited by 33
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
Alomran, R., White, M. A., Bruce, M., Bressel, M., Roache, S., Karroum, L., Hanna, G. G., Siva, S., Goel, S., & David, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08042-w · Cited by 26
Jahan, N., Jones, C., & Rahman, R. L. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111324 · Cited by 27
Al-Qasem, A. J., Alves, C. L., & Ditzel, H. J. (2021) · Cancers · doi:10.3390/cancers13215397 · Cited by 27
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature
Ozaki, Y., Miura, S., Oki, R., Morikawa, T., & Uchino, K. (2021) · Cancers · doi:10.3390/cancers14010196 · Cited by 33
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
Kripa, E., Rizzo, V., Galati, F., Moffa, G., Cicciarelli, F., Catalano, C., & Pediconi, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.987012 · Cited by 28
“For this reason, the current standard of care for most patients with ER-positive metastatic BC consists in CDK 4/6 inhibitors as first-line therapy, in association with aromatase inhibitors or combined with Fulvestrant, as second-line therapy (22, 23).”
BackgroundTinterri, C., Sagona, A., Barbieri, E., Grimaldi, S. D. M., Jacobs, F., Zambelli, A., Trimboli, R. M., Bernardi, D., Vinci, V., & Gentile, D. (2022) · Cancers · doi:10.3390/cancers14246237 · Cited by 26
Low, J. L., Lim, E. H., Bharwani, L. D., Wong, A. L. A., Wong, K., Ow, S. G. W., Lim, S. E., Lee, M., Choo, J. R. E., Lim, J. S. J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221139678 · Cited by 26
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Ashai, N., & Swain, S. M. (2023) · Cancers · doi:10.3390/cancers15061855 · Cited by 26
Gallanis, G. T., Sharif, G. M., Schmidt, M. O., Friedland, B., Battina, R., Rahhal, R., Davis, J. W., Khan, I., Wellstein, A., & Riegel, A. T. (2023) · Cancers · doi:10.3390/cancers15061908 · Cited by 25
Miyashita, M., Bell, J. S. K., Wenric, S., Karaesmen, E., Rhead, B., Kase, M., Kaneva, K., Vega, F. M. D. L., Zheng, Y., Yoshimatsu, T. F., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01627-2 · Cited by 25
“Hormone receptor-positive (HR+)/HER2- tumors have historically received endocrine therapy and, more recently, CDK4/6 inhibitors as targeted treatments [4, 5].”
BackgroundCell facilitation promotes growth and survival under drug pressure in breast cancer
Emond, R., Griffiths, J. I., Grolmusz, V. K., Nath, A., Chen, J., Medina, E. F., Sousa, R. S., Synold, T. W., Adler, F. R., & Bild, A. H. (2023) · Nature Communications · doi:10.1038/s41467-023-39242-6 · Cited by 30
Pu, D., Xu, D., Wu, Y., Chen, H., Shi, G., Feng, D., Zhang, M., Liu, Z., & Li, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05516-1 · Cited by 31
Güven, D. C., & Şahin, T. K. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07226-1 · Cited by 26
“The cyclin-dependent kinase (CDK) 4/6 inhibitors significantly altered the treatment landscape of hormone-positive (HR+), HER2-metastatic breast cancer (MBC) [1–3].”
BackgroundKoleva‐Kolarova, R., Oktora, M. P., Robijn, A. L., Greuter, M. J. W., Reyners, A. K. L., Buskens, E., & de Bock, G. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.001 · Cited by 25
Iwata, S., Tatsumi, Y., Yonemoto, T., Araki, A., Itami, M., Kamoda, H., Tsukanishi, T., Hagiwara, Y., Kinoshita, H., Ishii, T., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8086 · Cited by 26
Gagliano, A., Prestifilippo, A., Cantale, O., Ferini, G., Fisichella, G., Fontana, P., Sciacca, D., & Giuffrida, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643155 · Cited by 26
Şahin, T. K., Kavgacı, G., Güven, D. C., & Aksoy, S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102956 · Cited by 24
Burciu, O. M., Merce, A.-G., Cerbu, S., Iancu, A., Popoiu, T.-A., Cobec, I. M., Sas, I., & Dimofte, G. M. (2025) · Medicina · doi:10.3390/medicina61071280 · Cited by 33
“Meanwhile, by extending these findings to patients with endocrine-resistant disease, the PALOMA-3 study showed significant benefits of administrating palbociclib together with fulvestrant [54].”
Raphael, J., Desautels, D. N., Pritchard, K. I., Petkova, E., & Shah, P. S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.010 · Cited by 25
Sammons, S. L., Kornblum, N. S., & Blackwell, K. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0587-9 · Cited by 27
Malmgren, J. A., Hurlbert, M. S., Atwood, M. K., & Kaplan, H. G. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05090-y · Cited by 24
Durable response to palbociclib and letrozole in ovarian cancer withCDKN2Aloss
Frisone, D., Charrier, M., Clément, S., Christinat, Y., Thouvenin, L., Homicskó, K., Michielin, O. A., Bodmer, A., Chappuis, P. O., McKee, T., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1685291 · Cited by 27
Lin, M., Chen, Y., Jin, Y., Hu, X., & Zhang, J. (2020) · Journal of Cancer · doi:10.7150/jca.48944 · Cited by 25
“After PALOMA-1, ribociclib-based MONALEESA-2[14], MONALEESA-3[12], MONALEESA-7[13] and palbociclib-based PALOMA-2[17], PALOMA-3[8] and abemaciclib-based MONARCH-2[15], MONARCH-3[16] all showed the superiority of CDK4/6 inhibitors-containing regimens over endocrine therapy alone.”
MethodRegulation of aromatase expression: Potential therapeutic insight into breast cancer treatment
Molehin, D., Filleur, S., & Pruitt, K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111321 · Cited by 27
“palbociclib in treating postmenopausal women with ER-positive HER2-negative advanced breast cancer (Finn et al., 2016).”
Lee, J. S., Yost, S. E., Li, S. M., Cui, Y., Frankel, P. H., Yuan, Y., Schmolze, D., Egelston, C. A., Guo, W., Murga, M., et al. (2022) · Cancers · doi:10.3390/cancers14133159 · Cited by 25
Cosimo, S. D., Pérez-García, J. M., Bellet, M., Dalenc, F., Gil‐Gil, M., Borrego, M. R., Gavilá, J., Sampayo-Cordero, M., Aguirre, E., Schmid, P., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac205 · Cited by 28
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S., Kim, G. M., Kim, T. Y., Ryu, W., Kim, J. Y., Park, H. S., Park, S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01601-4 · Cited by 27
“in the PALOMA‐2 study Next, we validated our findings using the PALOMA-2 study [9].”
BackgroundMethodInfluentialThe Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
“The prolonged PFS in patients treated with palbociclib and ET was further confirmed in the PALOMA-2 trial, where 666 patients were included, with a median PFS of 24.8 versus 14.5 months when comparing the combination with letrozole alone (HR 0.58, 95% CI 0.46–0.72, p 0.001) [30].”
InfluentialVasseur, A., Cabel, L., Hego, C., Taka, W., Trabelsi‐Grati, O., Renouf, B., Lerebours, F., Loirat, D., Brain, E. G. C., Cottu, P. H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02986-6 · Cited by 24
“Three CDK4/6i (palbociclib, ribociclib and abemaciclib) [2 – 4] in combination with aromatase inhibitors [5] or fulvestrant (a selective estrogen receptor degrader) [6] have extended progression-free survival (PFS) and overall survival (OS) [7].”
BackgroundShe, Y., Guo, Z., Zhai, Q., Liu, J., Du, Q., & Zhang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1378090 · Cited by 27
Cortés, J., Hurvitz, S. A., O’Shaughnessy, J., Delaloge, S., Iwata, H., Rugo, H. S., Neven, P., Kanagavel, D., Cohen, P., Paux, G., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02036 · Cited by 24
Self-citationCurigliano, G., Criscitiello, C., Espósito, A., Intra, M., & Minucci, S. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1318848 · Cited by 24
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Pan, Q., Sathe, A., Black, P. C., Goebell, P. J., Kamat, A. M., Schmitz‐Dräger, B. J., & Nawroth, R. (2017) · Bladder Cancer · doi:10.3233/blc-170105 · Cited by 28
Freedman, R. A., & Tolaney, S. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4560-6 · Cited by 26
Han, G. C., Hwang, J. H., Wankowicz, S. A. M., Zhang, Z., Liu, D., Cibulskis, C., Gaviola, G. C., Ghazikhanian, V., McKay, R. R., Bubley, G. J., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00140 · Cited by 24
Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients
Rascon, K., Flajc, G., Angelis, C. D., Liu, X., Trivedi, M. V., & Ekinci, E. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018817904 · Cited by 25
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Chacón, J. I., de la Cruz‐Merino, L., Gregori, J. G., de Dueñas, E. M., Oliveira, M., Seguí, M. Á., Álvarez, I., Antolín, S., Bellet, M., & López‐Tarruella, S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02010-w · Cited by 31
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK–cyclin D1/CDK4 pathway
Wang, S., Wang, X., Gao, Y., Yingxia, P., Dong, N., Xie, Q. R., Zhang, X., Wu, Y., Li, M., & Li, J. (2019) · The Journal of Pathology · doi:10.1002/path.5246 · Cited by 25
“Importantly, palbociclib, a small-molecule inhibitor of CDK4 and CDK6, combined with letrozole has recently been approved to treat postmenopausal women with ER-positive, HER2-negative advanced breast cancer as a first-line therapy [35].”
Inoue, K., Masuda, N., Iwata, H., Takahashi, M., Ito, Y., Miyoshi, Y., Nakayama, T., Mukai, H., van der Walt, J., Mori, J., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01239-8 · Cited by 25
Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
Shao, X., Zheng, Y., Cao, W., Shen, X., Li, G., Chen, J., Huang, Y., Huang, P., Shi, L., Ye, W.-W., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1340 · Cited by 26
“Many phase III randomized trials have demonstrated the effectiveness of CDK4/6i in both first-line (9-12) and endocrine-resistant settings (12-14).”
BackgroundBi, H., Shang, J., Zou, X., Xu, J., & Han, Y. (2021) · Oncology Letters · doi:10.3892/ol.2021.12864 · Cited by 27
“The interaction of cyclin D with CDK4 and CDK6 promotes the phosphorylation of the retinoblastoma gene product, which in turn leads the cell cycle from the G1 phase to the S phase (22).”
BackgroundRath, S., Elamarthi, P., Parab, P. A., Gulia, S., Nandhana, R., Mokal, S., Kembhavi, Y., Perumal, P., Bajpai, J., Ghosh, J., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253722 · Cited by 24
“Palbociclib was well tolerated at the 125 mg dose, with only 32% patients requiring dose reduction compared with 36% requiring dose reduction in PALOMA-2 [2] and 34% in PALOMA-3 trial [4].”
MethodResultInfluentialMasuda, N., Tamura, K., Yasojima, H., Shimomura, A., Sawaki, M., Lee, M.-J., Yuno, A., Trepel, J. B., Kimura, R., Nishimura, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08973-4 · Cited by 25
Yang, V. W. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00008-6 · Cited by 27
Raghavendra, A. S., Kettner, N. M., Kwiatkowski, D. N., Damodaran, S., Wang, Y., Ramirez, D. L., Gombos, D. S., Hunt, K. K., Shen, Y., Keyomarsi, K., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00722-1 · Cited by 24
Du, Y., Yan, D., Yuan, Y., Xu, J., Wang, S., Yang, Z., Cheng, W., Tian, X., & Kan, Q. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1577665 · Cited by 24
Gao, H., Lin, Y., Zhu, T., Ji, F., Zhang, L., Yang, C.-Q., Yang, M., Li, J., Cheng, M., & Wang, K. (2021) · The Breast · doi:10.1016/j.breast.2021.07.002 · Cited by 25
Paoletti, C., Barlow, W. E., Cobain, E. F., Bergqvist, M., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., Pusztai, L., Sharma, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1562 · Cited by 23
Re, M. D., Crucitta, S., Omarini, C., Bargagna, I., Mongillo, M., Palleschi, M., Stucci, S., Meattini, I., D'Onofrio, R., Lorenzini, G., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.10.005 · Cited by 23
Ademuyiwa, F. O., Northfelt, D., O’Connor, T. L., Levine, E. G., Luo, J. R., Tao, Y., Hoog, J., Laury, M. L., Summa, T., Hammerschmidt, T., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-022-00504-z · Cited by 23
Karaçin, C., Öksüzoğlu, B. Ç., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., Selvi, O., Erdem, D., Avşar, E., Paksoy, N., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10609-8 · Cited by 23
“A significant PFS contribution of CDK inhibitors has been demonstrated in randomized clinical trials in which CDK4/6 inhibitors were used with endocrine therapies [5, 6].”
BackgroundRegulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition
Hu, Q., & Huang, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108939 · Cited by 26
Shu, Y., Wang, L., Ding, Y., & Zhang, Q. (2023) · Drug Safety · doi:10.1007/s40264-023-01334-z · Cited by 22
Brufsky, A., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., & Rugo, H. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1237751 · Cited by 23
“Notably, in the P-REALITY X study, the median age of patients after stabilized inverse probability treatment weighting (sIPTW) was 70 years in both treatment groups, which is 8–9 years older than the median age in the PALOMA-2 trial (20, 21).”
Self-citationAl-Ziftawi, N. H., Elazzazy, S., Alam, M. F., Shafie, A. A., Hamad, A. A., Bbujassoum, S., & Ibrahim, M. I. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203684 · Cited by 24
Chen, A., Kim, B.-J., Mitra, A., Vollert, C. T., Lei, J. T., Fandino, D. M., Anurag, M., Holt, M. V., Gou, X., Pilcher, J. B., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0564 · Cited by 24
“There are currently three FDA-approved CDK4/6 inhibitors-palbociclib, abemaciclib, and ribociclib (45–48).”
BackgroundCDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats
Sacaan, A. I., Thibault, S., Hong, M., Kondegowda, N. G., Nichols, T., Li, R., Rosselot, C., Evering, W., Fenutría, R., Vitsky, A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0172 · Cited by 25
Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy
Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0855-5 · Cited by 25
“monotherapy, although are associated with myelosuppression due to on-target CDK4/6 inhibition [39, 40], which may make them less suitable for some patients.”
BackgroundStearns, V., Brufsky, A., Verma, S., Cotter, M. J., Lu, D. R., Dequen, F., & Joy, A. A. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.007 · Cited by 23
Self-citationLerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, H. R., Rivera, S., MacGrogan, G. M., Mouret‐Reynier, M., de Lara, C. T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0733-x · Cited by 23
Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer
Cabetas, M. G.-T., Martínez, P. L., Jiménez‐Nácher, I., Díaz‐Almirón, M., Zamora, P. M., & Ambrosio, A. H. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01193-z · Cited by 25
Franzoi, M. A., Saúde-Conde, R., Cristóvão‐Ferreira, S., Eiger, D., Awada, A. H., & de Azambuja, E. (2021) · The Breast · doi:10.1016/j.breast.2021.03.002 · Cited by 24
“For example, with respect to the combination of CDK 4/6 inhibitors and endocrine therapy, which confers impressive response rates of ~50% for patients with visceral metastases [18,29], visceral crisis and high disease’s burden were explicit exclusion criteria in the PALOMA 2[30], PALOMA 3[31], MONALEESA-3[32] and MONA…”
BackgroundOno, M., Oba, T., Shibata, T., & Ito, K. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03722-3 · Cited by 23
Kjoe, P. R. L. M., van der Wall, E., & Schagen, S. B. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.08.002 · Cited by 24
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23
“On the basis of the PALOMA-2 [19,20] and PALOMA-3 [21,22] trials, palbociclib was approved for the treatment of HR-positive/HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or with fulvestrant in women who had received prior ET.”
MethodPI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom
Schettini, F., Buono, G., Trivedi, M. V., Placido, S. D., Arpino, G., & Giuliano, M. (2017) · Breast Care · doi:10.1159/000481657 · Cited by 25
Teh, J. L. F., Erkes, D. A., Cheng, P. F., Tiago, M., Wilski, N. A., Field, C. O., Chervoneva, I., Levesque, M. P., Xu, X., Dummer, R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0743 · Cited by 22
“Highly selective CDK4/6 inhibitors (CDK4/6i) are currently FDA approved for estrogen receptor–positive (ERþ) breast cancer in combination with hormone signaling blockade (5).”
BackgroundUpdate Breast Cancer 2017 – Implementation of Novel Therapies
Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., Ettl, J., et al. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-122885 · Cited by 22
“Even though many studies have demonstrated the significant benefits of CDK4/6 inhibitors with regard to PFS [20 – 24], data on overall survival (OS) are currently still lacking.”
Shimoi, T., Sagara, Y., Hara, F., Toyama, T., & Iwata, H. (2020) · Breast Cancer · doi:10.1007/s12282-020-01054-7 · Cited by 23
“Finn 2016 [14] PALOMA 2 PAL+LETa 444 24.”
Shen, Z., Wang, J., Ke, K., Chen, R., Zuo, A., Zhang, R., Wan, W., Xie, X., Li, X., Song, N., et al. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1991121 · Cited by 22
“compounds such as PD-0332991 (commercial name as Palbociclib) that specifically block CDK4/6 leads to G1 arrest in cell culture and xenograft models, thus, Palb had passed through the clinical trial and was finally approved for breast cancer chemotherapy [7].”
BackgroundRetractedMycock, K., Zhan, L., Hart, K., Taylor‐Stokes, G., Milligan, G., Atkinson, C., & Mitra, D. (2021) · Future Oncology · doi:10.2217/fon-2021-0716 · Cited by 22
Sharaf, B., AlMasri, R., Abdel-Razeq, N., Salama, O., Hamad, I., Abunasser, M., & Abdel‐Razeq, H. (2022) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s344867 · Cited by 24
Chow, R., Lage, D. E., Williams, G. R., Sedrak, M. S., Greer, J. A., Temel, J. S., & Nipp, R. D. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7055 · Cited by 25
“…(95% CI) 0.52 (0.31–0.86)Baselga et al, 2012 (CLEOPATRA) 65–74 year olds Baselga et al, 2012 (CLEOPATRA) ≥75 year olds Mehta et al, 2012 (S0026) Finn et al, 2016 (PALOMA-2) Goetz et al, 2017 (MONARCH 3) Hortobagyi et al, 2018 (MONALEESA-2) Slamon et al, 2018 (MONALEESA-3) 0.55 (0.12–2.54)…”
BackgroundInfluentialExpert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
Torregrosa, M. D., Barco, S. D., Cotes, A., Roso, L. L., Servitja, S., & Sarrió, R. G. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02766-8 · Cited by 24
“Its approval was based on the results of two phase III trials: PALOMA-2 evaluated the use of letrozole with or without palbociclib in patients with MBC who had not received previous systemic treatment [31], and PALOMA-3 compared the use of fulvestrant with or without palbociclib in the pre- and postmenopausal populati…”
MethodFu, H., Wu, Z., Lei, Z., Teng, Q., Yang, Y., Ashby, C. R., Lei, Y., Lian, Y., & Chen, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.861642 · Cited by 25
“A recent clinical trial reported that in patients with previously untreated ER-positive, HER2-negative advanced breast cancer, the combination of palbociclib with letrozole produced a longer progression-free survival than letrozole alone (Finn et al., 2016).”
BackgroundHamilton, E. P., Cortés, J., Özyılkan, Ö., Chen, S., Petráková, K., Manikhas, A., Jérusalem, G., Hegg, R., Huober, J., Zhang, W., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06662-9 · Cited by 28
CDK 4/6 inhibitors for the treatment of meningioma
Young, J. S., Kidwell, R. L., Zheng, A., Haddad, A. F., Aghi, M. K., Raleigh, D. R., Schulte, J. D., & Butowski, N. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931371 · Cited by 23
“CCND1 amplification and loss of p16 expression may indicate sensitivity to CDK inhibitors in breast cancer, although results are conflicting in the literature (19, 27).”
ResultChoong, G. M. Y., Liddell, S. S., Ferre, R. A. L., O'Sullivan, C. C., Ruddy, K. J., Haddad, T. C., Hobday, T. J., Peethambaram, P. P., Liu, M., Goetz, M. P., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06713-1 · Cited by 24
“1—NR)] [6], while slightly shorter in the 2L setting [19 months (95% CI 15.”
BackgroundYıldırım, H. Ç., Mutlu, E., Chalabiyev, E., Özen, M., Keskinkılıç, M., Ön, S., Çelebi, A., Dursun, B., Acar, Ö., Kahraman, S., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.09.009 · Cited by 23
“Our safety data in male patients were comparable to phase 3 studies in female patients [6,16,18].”
BackgroundResultMlinarić, Z., Turković, L., Begović, I., Nigović, B., & Sertić, M. (2022) · Molecules · doi:10.3390/molecules27217603 · Cited by 22
Çağlayan, D., Koçak, M. Z., Geredeli, Ç., Tatlı, A. M., Göksu, S. S., Eryılmaz, M. K., Araz, M., & Artaç, M. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03435-7 · Cited by 23
CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis
Wu, C., Xie, T., Guo, Y., Wang, D., Qiu, M., Han, R., Qing, G., Liang, K., & Liu, H. (2023) · Oncogene · doi:10.1038/s41388-023-02653-2 · Cited by 25
Yıldırım, E. Ç., Atağ, E., Çoban, E., Ünal, O. Ü., Çelebi, A., Keser, M., Uzun, M., Keskinkılıç, M., Şimşek, E. T., Sarı, M., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.06.006 · Cited by 25
Wang, X., Shi, W., Wang, X., Lu, J., He, P., Zhang, H., & Chen, X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01658-w · Cited by 25
“Palbociclib (Ibrance, Pal) is a selective inhibitor of cyclindependent kinase 4/6 (CDK4/6) approved by the Food and Drug Administration (FDA) in 2015 for the treatment of hormone receptor-positive (HR)/HER2 negative (HER2) breast cancer in combination with hormone therapies [5].”
BackgroundPrat, A., Solovieff, N., André, F., O’Shaughnessy, J., Cameron, D., Janni, W., Sonke, G. S., Yap, Y. S., Yardley, D. A., Partridge, A. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0561 · Cited by 25
Poulet, S., Dai, M., Wang, N., Yan, G., Boudreault, J., Daliah, G., Guillevin, A., Nguyen, H., Galal, S., Ali, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02029-4 · Cited by 24
“Using lower concentrations of palbociclib, while still achieving comparable or even stronger anti-tumor responses while TGFβ3 levels are elevated, could help prevent some of the associated on-target toxicity in patient [37].”
BackgroundGastrointestinal Metastases From Lobular Breast Carcinoma: A Literature Review
Kioleoglou, Z., Georgaki, E., Koufopoulos, N. I., Köstek, O., Volakakis, N., Dimitriadou, A., & Kokkali, S. (2024) · Cureus · doi:10.7759/cureus.65852 · Cited by 23
“The results of PALOMA-2, MONALEESA-2, and MONARCH-3 trials led to FDA and EMA approval of palbociclib, ribociclib, and abemaciclib respectively [103-105].”
BackgroundCyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future
Siskin, M., Economides, M. P., & Wise, D. R. (2025) · Cancers · doi:10.3390/cancers17050774 · Cited by 24
“Despite their significant activity in breast cancer, their efficacy in prostate cancer has been limited [70–75 , 79– 82 ].”
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Hou, Y., Ji, K., Sun, Y., Zhang, L.-N., & Chen, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2026-9 · Cited by 22
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.